690632-25-8

Usage

Uses

Used in Recreational Drug Use:
AM-2201 is used as a recreational drug for its psychoactive effects, providing users with a potent and long-lasting high. Its popularity stems from the intensity and duration of the experience it offers.
Used in Research Applications:
In scientific research, AM-2201 is utilized as a research chemical to study the effects and mechanisms of action of cannabinoid receptors. It aids in understanding the role of these receptors in various physiological and pathological processes, potentially leading to the development of new therapeutic agents.
Used in Pharmaceutical Development:
Although not approved for medical use, AM-2201's interaction with cannabinoid receptors makes it a candidate for pharmaceutical development. Researchers may explore its potential applications in treating conditions that could benefit from modulation of the endocannabinoid system, such as chronic pain, inflammation, and neurological disorders.

InChI:InChI=1/C12H11F3N2S/c1-7-10(6-16)18-11(17-7)8-2-4-9(5-3-8)12(13,14)15/h2-5H,6,16H2,1H3

Upstream product

• 317318-96-0 [4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-methanol 
• 175277-03-9 4-methyl-2-[4-(trifluoromethyl)phenyl]thiazole-5-carboxylic acid ethyl ester 
• 72505-21-6 4-trifluoromethylbenzthioamide 
• 439134-78-8 5-(bromomethyl)-4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole 
• 929693-86-7 2-({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)-1H-isoindole-1,3(2H)-dione 

Downstream Products

• 929693-87-8 ethyl 2-methyl-2-[(4-{[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)amino]carbonyl}phenyl)oxy]propanoate 

Relevant academic research and scientific papers

Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARα agonists. 1. Discovery of a novel series of potent HDLc raising agents

The peroxisome proliferator activated receptors PPARα, PPARγ, and PPARδ are ligand-activated transcription factors that play a key role in lipid homeostasis. The fibrates raise circulating levels of high-density lipoprotein cholesterol and lower levels of triglycerides in part through their activity as PPARα agonists; however, the low potency and restricted selectivity of the fibrates may limit their efficacy, and it would be desirable to develop more potent and selective PPARα agonists. Modification of the selective PPARδ agonist 1 (GW501516) so as to incorporate the 2-aryl-2-methylpropionic acid group of the fibrates led to a marked shift in potency and selectivity toward PPARα agonism. Optimization of the series gave 25a, which shows EC50 = 4 nM on PPARα and at least 500-fold selectivity versus PPARγ and PPARγ. Compound 25a (GW590735) has been progressed to clinical trials for the treatment of diseases of lipid imbalance.